The data presented by the Fang team confirmed that blocking the expression of one of the EBV surface proteins LMP1 or PD-L1 could be used as a therapy against nasopharyngeal carcinoma [63,64]. The gene discussed is PDLIM7; the disease is nasopharyngeal carcinoma.